^
    4d
    Preliminary Exploratory Clinical Study of TC-D101 in the Treatment of DLL3-Positive Relapsed/Refractory Primary Small-Cell Lung Cancer (ChiCTR2500112639)
    P=N/A, N=8, Not yet recruiting, Eastern Theater Command General Hospital of the Chinese People's Liberation Army (Jinling Hospital, Affiliated to Nanjing University Medical School);
    New trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    4d
    Preliminary Exploratory Clinical Study of TC-G203 for the Treatment of GPC3-Positive Recurrent/Metastatic Solid Tumors (ChiCTR2500112333)
    P=N/A, N=14, Not yet recruiting, Beijing Gaobo Hospital; Beijing Gaobo Hospital
    New trial
    |
    GPC3 (Glypican 3)
    4d
    An early clinical study to evaluate the safety and clinical efficacy of STR-P004 in subjects with relapsed/refractory CD19-positive acute lymphoblastic leukemia (ChiCTR2500111445)
    P=N/A, N=30, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New trial
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    4d
    A Phase 1, First-in-Human, Investigator-Initiated, Open-label Study to Assess the Safety, Feasibility, Cytokinetics, and Preliminary Antitumor Activity of GC511B in Adult Subjects with DLL3+ Relapsed/Refractory Small Cell Lung Cancer (ChiCTR2500111823)
    P1, N=100, Not yet recruiting, CancerCancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences Hospital
    New P1 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    11d
    To Evaluate the Safety and Tolerability of STR-P004 for the Treatment of Immune-mediated Kidney Diseases (clinicaltrials.gov)
    P=N/A, N=9, Not yet recruiting, Starna Therapeutics
    New trial
    |
    CD19 positive
    13d
    TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, Beijing GoBroad Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    GPC3 (Glypican 3)
    |
    cyclophosphamide • fludarabine IV
    13d
    Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC (clinicaltrials.gov)
    P1, N=12, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P1 trial
    20d
    CARAML: Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell Transplantation (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Great Ormond Street Hospital for Children NHS Foundation Trust | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2025 --> Jun 2026
    Enrollment closed • Trial primary completion date
    |
    CD33 (CD33 Molecule)
    |
    BE CAR33 T
    2ms
    This Study is an Open-lable, Phase I Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer. (clinicaltrials.gov)
    P1, N=55, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P1 trial • First-in-human
    2ms
    TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC (clinicaltrials.gov)
    P1, N=24, Recruiting, TCRCure Biopharma Ltd.
    New P1 trial
    |
    cyclophosphamide • fludarabine IV
    2ms
    To Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of STR-P004 (clinicaltrials.gov)
    P=N/A, N=11, Not yet recruiting, Starna Therapeutics
    New trial
    2ms
    TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Beijing GoBroad Hospital
    New P1 trial
    |
    cyclophosphamide • fludarabine IV